Reporter Lu Yu of China's ** newspaper.
The pharmaceutical territory of China General Technology Group, a state-owned enterprise, may be further expanded.
On the evening of February 5, Heavy Pharmaceutical Holdings and China National Pharmaceutical announced at the same time that Chongqing Chemical and Medical Holdings is carrying out the strategic integration of Chongqing Pharmaceutical with China General Technology Group, which may lead to the change of the controlling shareholder and actual controller of Chongqing Pharmaceutical, which may lead to competition with Chinese pharmaceutical peers.
Previously, on January 22, Yuan Quan, chairman of Heavy Pharmaceutical Holdings, increased his holdings in the company by 21 through bidding transactions240,000 shares, an increase of about 95580,000 yuan.
China General Motors or Chongqing Pharmaceutical
Heavy Pharmaceutical Holdings announced on the evening of February 5 that it received a notification letter from the company's controlling shareholder, Chongqing Pharmaceutical and Health Industry, that the indirect controlling shareholder, Chongqing Chemical Medicine Holding (Group) Company, is carrying out the strategic integration of Chongqing Pharmaceutical with China General Technology (Group) Holding Co., Ltd., which may lead to a change in the controlling shareholder and actual controller of Chongqing Pharmaceutical, which may lead to a change in the actual controller of the company.
However, the matter is still in the planning stage.
Chongqing Chemical & Medical Holdings Co., Ltd. is a wholly state-owned enterprise under the State-owned Assets Supervision and Administration Commission of Chongqing Municipality, and its current business mainly includes three major sectors: new chemical materials, medicine and health, and new service industries. Among them, the main company in the pharmaceutical and health sector is Chongqing Pharmaceutical, which includes three businesses: pharmaceutical business, pharmaceutical industry, and medical care and health, and its pharmaceutical business segment is centered on Heavy Pharmaceutical Holdings.
Founded in December 2018, Chongqing Pharmaceutical is a joint shareholding enterprise of Chongqing Chemical and Medical Holdings, China General Technology Group and its holding subsidiary China Pharmaceutical, a financing platform, an investment platform and an industrial integration platform for Chongqing's state-owned pharmaceutical and health industry, and a pilot enterprise for the "Double Hundred Action" implemented by the State-owned Assets Supervision and Administration Commission of the State-owned Assets Supervision and Administration Commission.
At present, Chongqing Pharmaceutical holds 3847% equity, Chongqing Chemical Medical Holdings, China General Technology and China Pharmaceutical hold 51% equity, 22% equity and 27% equity of Chongqing Pharmaceutical respectively.
Chairman of Sinopharm HoldingsIn late January, it spent 950,000 yuan to increase its holdings
On December 28, 2023, Sinopharm Holdings announced that based on the confidence in the company's operation and development and the full recognition of the company's long-term investment value and future sustainable development prospects, Yuan Quan, chairman of Sinopharm Holdings, plans to increase his holdings of the company's shares within six months from the date of disclosure of the announcement, and intends to use no more than 1 million yuan (inclusive) of its own funds to increase his holdings.
According to the official website of the Shenzhen Stock Exchange, on January 22, 2024, Yuan Quan, chairman of Heavy Pharmaceutical Holdings, increased his holdings in the company by 21240,000 shares, with an average transaction price of 45 yuan shares, the amount of increase is about 95580,000 yuan. Previously, Yuan Quan had been listed on October 27, 2023, at a price of 4The average price of 91 yuan **18560,000 shares of Heavy Pharmaceutical Holdings**.
In the future, it may face competition in the same industry
In recent years, China General Technology has focused on the three main businesses of advanced manufacturing and technical services, medicine and medical health, and engineering services, and China National Pharmaceutical is one of the two listed companies in its pharmaceutical and health sector.
According to the official website, China General Technology has 92 pharmaceutical commercial branches and 403 medical institutions in 30 provinces and cities across the country, and operates more than 6,000 pension beds in 40 health care institutions of various types in 16 provinces and cities across the country.
The predecessor of Sinopharm Holdings was the Southwest Branch of China Pharmaceutical Company, a Chinese pharmaceutical company founded in 1950.
China Pharmaceutical also announced on the evening of February 5 that if China General Technology obtains control of Chongqing Pharmaceutical, which may lead to competition with the company's peers, General Technology Group will strictly comply with the provisions of relevant laws and regulations to fulfill its commitments and timely fulfill its information disclosure obligations.
Under such circumstances, if China General Technology successfully controls Chongqing Pharmaceutical in the future, it is worth paying attention to whether Heavy Pharmaceutical Holdings and China Pharmaceutical will face the integration of related assets.
Previously, China General Technology had fulfilled its commitment to inject its related machine tool assets into its controlled listed company Shenyang Machine Tool.
The restructuring of pharmaceutical leaders continues
In recent years, the relevant pharmaceutical leaders have expanded their strength through restructuring, including the three major pharmaceutical central enterprises, as well as relevant local pharmaceutical leaders.
Among the three major pharmaceutical state-owned enterprises, China Resources Group and China General Technology's pharmaceutical sector have developed and grown through continuous acquisition of related assets.
In recent years, Sinopharm Group has built the world's largest modern Chinese medicine industrial manufacturing industry cluster through a series of restructuring and integration, including mergers and acquisitions of Yingtian Pharmaceutical, Tongjitang, Tianjiang Pharmaceutical, Yifang Pharmaceutical, and Taiji Group, a listed company of traditional Chinese medicine in Chongqing.
China Resources Group has also continued to expand its pharmaceutical territory through mergers and acquisitions, and in recent years, its important move is to become the owner of Boya Biotech, a listed company of blood products, in 2021, and intends to further expand in this field.
Shanghai Pharmaceutical, a leading state-owned local pharmaceutical company, has also participated in the mixed-ownership reform of Tianjin Pharmaceutical Group, which has a well-known listed pharmaceutical company, Darentang, through relevant means.
Editor: Xiaomo Review: Muyu